Group B Streptococcus

Group B streptococcus (GBS) infection is the infection caused by the bacterium Streptococcus agalactiae. Group B streptococcal infection can cause serious illness and sometimes death, especially in newborns, the elderly, and people with compromised immune systems. In general, GBS is a harmless commensal bacterium being part of the human microbiota colonizing the gastrointestinal and genitourinary tracts of up to 30% of healthy human adults (asymptomatic carriers).

Vaginal colonization rates range from 4 to 36%, with most studies reporting over 20%. GBS is the main cause of bacterial infections in newborns, such as septicemia, pneumonia, and meningitis, which can lead to death or long-term after effects. Infections in newborns are separated into two clinical types, early-onset disease (EOGBS) and late-onset disease (LOGBS). EOGBS manifests from 0 to 7 living days in the newborn, most of the cases being apparent within 24 hr. LOGBS starts between 7 and 90 days after birth. EOGBS is acquired through exposure of the fetus or baby to GBS from the vagina either in utero or during birth.

available-testAvailable Test

Group B streptococcus Panel

testTest Information

Organism List:

Staphylococcus agalactiae

Clinical Utility:

Retrogen offers early & accurate detection, rapid turnaround times, and only requires a single, non-invasive sample collection. Your referring physician will be provided with a detailed, comprehensive report that leads to actionable decisions and forward treatment options.

Method:

Retrogen carries out real-time molecular PCR on DNA extracted from vaginal swabs to screen for microorganisms. This quantitative approach uses TaqMan chemistry from Life Technologies to detect pathogen specific gene sequences. Ordering

order Ordering

Test ID:

Turn-around Time:

Preferred Specimen:

#8003

24-48 hours

Vaginal swab

billing Billing

CPT Codes:

Billing Information:

87081, 87150. MIC performed add charge 87186 or 87184

View Billing Information

refer Refernce
  1. Amsel R, Totten PA, Spiegel CA, et al. Nonspecific vaginitis: Diagnostic criteria and microbial and epidemiologic associations. Am J Med 74(1):14-22, 1983.
  2. Verstraelen H, Verhelsy R. Bacterial vaginosis: An update on diagnosis and treatment. Expert Rev Anti Infect Ther 7(9):1109-1124, 2009.
  3. Spiegel C, Amsel R, Holmes K. Diagnosis of bacterial vaginosis by direct gram stain of vaginal fluid. J. Clin. Microbiol. July 1983 vol. 18 no. 1, 170-177.
  4. Workowski, KA; Berman, S; Centers for Disease Control and Prevention, (CDC) (17 December 2010). "Sexually transmitted diseases treatment guidelines, 2010." MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports / Centers for Disease Control. 59 (RR-12): 1-110.
  5. Warner L, Klausner JD, Rietmeijer CA, et al. Effect of a brief video intervention on incident infec- tion among patients attending sexually transmitted disease clinics. PLoS Med 2008;5:919-27..
  6. Clement, Meredith E.; Okeke, N. Lance; Hicks, Charles B. (2014). "Treatment of Syphilis". JAMA. 312 (18): 1905.
contact

QUESTIONS ABOUT PRODUCTS OR SERVICES,

CALL 1-800-RETROGEN OR (858) 455-8411